I’m Fei, a Research Scientist at Google DeepMind (since 2026), where I’m currently interested in using AI to make biological discoveries.
Designing therapeutics for human health
- 2025 – Designed de novo antibodies and mini-binders, both validated in the wet lab.
- 2025 – Designed state-of-the-art DNA regulatory elements for DNA-based therapeutics.
- 2024 – Designed regulatory elements for ultra-stable mRNA, enabling an in vivo CAR-T therapy that outperformed the leading benchmark in non-human primates.
- 2023 – First use of generative models to engineer CRISPR–Cas.
- 2023 – Joined Lila Sciences as a founding member.
Designing enzymes for global sustainability
- 2019 – Joined R&D at Novonesis, where I designed commercial enzyme products across six classes, some used by billions of people worldwide:
- DNase (Pristine®)
- Mannanase (Mannaway®)
- Cellulase (Carezyme®)
- Carbonic anhydrase (carbon capture)
- Lipase
- PETase
Before that
- 2018 – During my postdoc with Robert Best at the NIH, we published what is arguably the first study to design highly diverse protein sequences with a generative model and validate them in the wet lab.
- 2014 – Earned my PhD in Physics from the Niels Bohr Institute at the University of Copenhagen, advised by Kresten Lindorff-Larsen, Wouter Boomsma, Mogens Høgh Jensen, and Daniel Otzen. There, we accurately predicted the structure of an amyloid protein by combining coevolution information with Monte Carlo sampling.